SGLT2 Protocol
A well-researched and clinically validated SGLT2 inhibitor protocol designed to optimize fat metabolism, reduce chronic inflammation, and improve metabolic flexibility.
Targets many molecular pathways, from nutrient sensing and metabolic flexibility to mitochondrial function and systemic inflammation.
Promotes fat oxidation and ketone production while targeting visceral fat, to fight inflammation, boost metabolic efficiency, and assist longevity.
Decreases systemic inflammation and glycemic stress that speed aging, helping to restore organ function toward healthier, more youthful levels.
(Featured In)
(Featured In)
Ahead of the field
“SGLT2 inhibitors… target senescent cells and modulate several aging pathways.”
“The hint here is that it’s actually slowing the aging rate.”
“SGLT2 inhibitors… target senescent cells and modulate several aging pathways.”
“The hint here is that it’s actually slowing the aging rate.”
“SGLT2 inhibitors… target senescent cells and modulate several aging pathways.”
“The hint here is that it’s actually slowing the aging rate.”
“SGLT2 inhibitors… target senescent cells and modulate several aging pathways.”
“The hint here is that it’s actually slowing the aging rate.”
Reset your metabolic clock
Targeting aging pathways
Simultaneously inhibits mTORC1 and activates AMPK - the same nutrient-sensing pathways targeted by caloric restriction and rapamycin - for comprehensive longevity benefits.
Enhancing metabolism
Mimics caloric restriction by shifting metabolism toward fat oxidation and mild ketogenesis while excreting 70-90g glucose daily, improving body composition without lifestyle changes.
Optimizing mitochondria
Promotes mitochondrial biogenesis and efficiency while reducing oxidative stress, supporting cellular energy production essential for healthy aging.
Reducing systemic inflammation
Decreases pro-inflammatory markers including TNF-α, IL-6, and SASP factors while reducing tissue inflammation that drives "inflammaging" and metabolic disease.
Reducing senescence burden
Research suggests metabolic optimization through SGLT2 inhibition may help reduce senescent cell accumulation and their harmful inflammatory signals, supporting tissue health and longevity.
Cardio-renal protection
Reduces heart failure risk and improves kidney markers independent of glucose control, with emerging evidence for all-cause mortality reduction.
Enhancing cardiac resilience
Improves heart performance through optimized ketone utilization and increased EPO production, supporting cardiovascular recovery and function.
Supporting brain fuel flexibility
Crosses blood-brain barrier to reduce neuroinflammation and modulate hypothalamic circuits, potentially protecting against cognitive decline and neurodegenerative diseases.
Optimizing body composition
Promotes modest weight loss and visceral fat reduction while preserving muscle mass, with enhanced benefits particularly pronounced in females.
Reducing pro-aging hormones
Specifically reduces senescent cell accumulation in metabolically active tissues like visceral fat and liver, addressing the root cause of age-related metabolic dysfunction.
Targeting metabolic senescence
Clears senescent cells from atherosclerotic plaques independent of cholesterol changes, targeting the cellular aging that drives cardiovascular disease progression.
Enhancing vascular health
Clears senescent cells from atherosclerotic plaques independent of cholesterol changes, targeting the cellular aging that drives cardiovascular disease progression.
Enhancing cardiac resilience
Preferentially reduces the harmful visceral fat around organs while preserving muscle mass, addressing the root cause of metabolic dysfunction and chronic disease risk.
Targeting visceral fat
Transforms white fat into metabolically active brown-like tissue through UCP1 upregulation and mitochondrial biogenesis, increasing energy expenditure and thermogenesis.
Activating brown fat pathways
Transforms white fat into metabolically active brown-like tissue through UCP1 upregulation and mitochondrial biogenesis, increasing energy expenditure and thermogenesis.
Cerebral insulin resistance
Addresses brain-specific insulin resistance and neuroinflammation that contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
Included with SGLT2
Healthspan personalized treatment protocols include professional clinical support on an ongoing basis. With MySpan, you can track your progress in real time—upload photos, record changes, and monitor how your protocol responds to treatment, all in one place.
Healthspan personalized treatment protocols include professional clinical support on an ongoing basis. With MySpan, you can track your progress in real time—upload photos, record changes, and monitor how your protocol responds to treatment, all in one place.
Hear from our patients
Reviews
129 reviews
Frequently asked questions
They reduce glucose reabsorption in the kidneys, causing excess glucose to be excreted through urine. This lowers blood sugar levels and shifts the body’s energy use toward stored fat.
SGLT2 inhibitors promote fat loss, reduce chronic inflammation, improve cardiovascular and kidney health, and activate longevity pathways like AMPK and mTORC1.
No. SGLT2 inhibitors have shown benefits in both diabetic and non-diabetic individuals for improving metabolic flexibility, reducing visceral fat, and lowering inflammation.
Your protocol includes tests for glucose, insulin, cholesterol, triglycerides, hs-CRP (inflammation), kidney markers, and more.
Most users notice energy improvements and less bloating within 2–4 weeks. Fat loss, glucose stability, and cardio-metabolic benefits build steadily over 3–6 months.
Yes. SGLT2 can be stacked with Rapamycin, Acarbose, or Metformin under clinician supervision for synergistic longevity benefits.
Some people experience increased urination or mild dehydration. Rarely, yeast infections or low blood sugar may occur. Your clinician will guide you on how to avoid or manage these.
Yes. All Healthspan protocols, labs, and prescriptions are HSA/FSA eligible.
SGLT2 inhibitors mimic many of the benefits of caloric restriction—like fat oxidation and metabolic efficiency—without requiring dietary changes.
No strict diet or fasting protocol is required, but lifestyle recommendations may enhance results.
Yes, but only under careful clinical guidance. SGLT2 inhibitors can be combined with GLP-1 receptor agonists, but this requires close monitoring to avoid low blood sugar, dehydration, or electrolyte imbalances. Your clinician will determine if this combination is appropriate and adjust your dosing plan accordingly.
Fat loss from SGLT2 inhibitors, particularly visceral fat, is often sustainable with continued use and healthy lifestyle support. However, it’s important to monitor kidney function, hydration status, and metabolic markers regularly to ensure safe, long-term results.
Initial improvements—such as better energy, reduced bloating, and appetite regulation—often appear within 2–4 weeks. Fat loss and metabolic benefits typically build over 8–12 weeks.
They reduce glucose reabsorption in the kidneys, causing excess glucose to be excreted through urine. This lowers blood sugar levels and shifts the body’s energy use toward stored fat.
SGLT2 inhibitors promote fat loss, reduce chronic inflammation, improve cardiovascular and kidney health, and activate longevity pathways like AMPK and mTORC1.
No. SGLT2 inhibitors have shown benefits in both diabetic and non-diabetic individuals for improving metabolic flexibility, reducing visceral fat, and lowering inflammation.
Your protocol includes tests for glucose, insulin, cholesterol, triglycerides, hs-CRP (inflammation), kidney markers, and more.
Most users notice energy improvements and less bloating within 2–4 weeks. Fat loss, glucose stability, and cardio-metabolic benefits build steadily over 3–6 months.
Yes. SGLT2 can be stacked with Rapamycin, Acarbose, or Metformin under clinician supervision for synergistic longevity benefits.
Some people experience increased urination or mild dehydration. Rarely, yeast infections or low blood sugar may occur. Your clinician will guide you on how to avoid or manage these.
Yes. All Healthspan protocols, labs, and prescriptions are HSA/FSA eligible.
SGLT2 inhibitors mimic many of the benefits of caloric restriction—like fat oxidation and metabolic efficiency—without requiring dietary changes.
No strict diet or fasting protocol is required, but lifestyle recommendations may enhance results.
Yes, but only under careful clinical guidance. SGLT2 inhibitors can be combined with GLP-1 receptor agonists, but this requires close monitoring to avoid low blood sugar, dehydration, or electrolyte imbalances. Your clinician will determine if this combination is appropriate and adjust your dosing plan accordingly.
Fat loss from SGLT2 inhibitors, particularly visceral fat, is often sustainable with continued use and healthy lifestyle support. However, it’s important to monitor kidney function, hydration status, and metabolic markers regularly to ensure safe, long-term results.
Initial improvements—such as better energy, reduced bloating, and appetite regulation—often appear within 2–4 weeks. Fat loss and metabolic benefits typically build over 8–12 weeks.